Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck's Ezetimibe Faces Reimbursement Threat In Europe

This article was originally published in The Pink Sheet Daily

Executive Summary

Results from the ENHANCE and ARBITER 6-HALTS trials may finally mean reduced coverage in Germany and the U.K.

You may also be interested in...

European HTA: Cancer Drugs Suffer At NICE, Whilst IQWiG And HAS Also Tighten Purse Strings

Economic austerity and the resulting pressure on health care spend leaves little room for maneuver among Europe’s health technology assessment agencies.

Lipitor Will Fade, Not Fall Off The Patent Cliff In Europe

Lipitor's European sales won't all disappear overnight, But the strong post-patent performance in Spain isunlikely to be replicated either.

Merck Releases Positive Study For Vytorin, But How Much Impact Will It Have?

A positive outcome in the SHARP study is good news for Merck, but questions still remain about the efficacy of Vytorin compared to older statins.

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts